The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of advers...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Maharaj, Kamira, Powers, John J., Achille, Alex, Mediavilla-Varela, Melanie, Gamal, Wael, Burger, Karen L., Fonseca, Renee, Jiang, Kun, Miskin, Hari P., Maryanski, Dave, Monastyrskyi, Andrii, Duckett, Derek R., Roush, William R., Cleveland, John L., Sahakian, Eva, Pinilla-Ibarz, Javier
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362385/
https://ncbi.nlm.nih.gov/pubmed/32634240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001800
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars